Osiris poised to lead stem cell drug market

12/27/2007 | Sun (Baltimore), The

Osiris Therapeutics may conquer the stem cell drug market in 2008, with clinical trials of its candidates showing promise. Three pivotal late-stage trials are under way to test intravenous drug Prochymal for Crohn's disease and graft-versus-host disease. The company also plans to conduct a Phase III trial for Chondrogen, which yielded positive results in midstage tests in treating knee pain caused by osteoarthritis.

View Full Article in:

Sun (Baltimore), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC